NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EMBioSys

EMBioSys

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://embiosys.com/

Last Round

Grant

Nov 25, 2025

Total Funding Raised

$1.59M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

EMBioSys is a medical technology company that develops non-invasive, wearable garments using induced electric field (iEF) therapy to treat aggressive cancers like triple-negative breast cancer.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Precision Medicine, Health IoT

Business Model

B2B

Customer Profile

Hardware + Subscription, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

induced electric field therapywearable cancer treatmenttumor treating fieldstriple-negative breast cancernon-invasive cancer therapycancer metastasis treatmentwearable medical deviceTNBCat-home cancer treatmentnon-pharmacological therapyiEF therapysolid tumor treatmentoncology medical deviceelectrode-free therapySBIR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EMBioSys Comparables

Compare EMBioSys with similar companies based on industry and business-model similarity.

EMBioSys comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Novocure
71%
QV Bioelectronics
61%
INIA Biosciences
57%

EMBioSys Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 25, 2025
SeedApr 30, 2025
GrantMay 9, 2024

EMBioSys Investors

Notable investors and investment history

EMBioSys investors
InvestorRounds
National Cancer InstituteGrant
NIH RADxGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 25, 2025

    Received $1.38M from National Cancer Institute and NIH RADx.

  • Apr 30, 2025

    Raised $3M in a seed funding round.

EMBioSys Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EMBioSys Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EMBioSys's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Year Founded2022
Last FundingNov 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.